Prof Xavier Leleu talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of weekly carfilzomib as a maintenance therapy in elderly patients with newly diagnosed multiple myeloma.
He describes this study, in which the researchers aimed to demonstrate the use of carfilzomib in these patients, as an alternative standard of care drug.
Prof Leleu also discusses the results from this phase I study, where patients underwent 13 cycles of maintenance. Only 4 patients from the study group were unable to complete this, however, overall this treatment was proven feasible and effective in elderly patients upfront.
He notes the potential incorporation of carfilzomib in the lenalidomide plus dexamethasone regimen for these patients in the future.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.